Gene therapy
The present invention provides an adeno-associated virus (AAV) vector gene therapy comprising a vascular endothelial growth factor (VEGF) C transgene; and a minimal nephropathy protein promoter NPHS1 or a podocyte promoter NPHS2. The gene therapy vector can be used for targeting podocytes in the glomerulus to treat or prevent kidney diseases, such as diabetic nephropathy..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 08. Nov. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
FOSTER RONALD R [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-11-08, Last update posted on www.tib.eu: 2023-12-05, Last updated: 2023-12-08 |
|---|
| Patentnummer: |
CN115315517 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016739299 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016739299 | ||
| 003 | DE-627 | ||
| 005 | 20231208115435.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016739299 | ||
| 035 | |a (EPA)CN115315517 | ||
| 035 | |a (EPA)70278767 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a FOSTER RONALD R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gene therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-11-08, Last update posted on www.tib.eu: 2023-12-05, Last updated: 2023-12-08 | ||
| 520 | |a The present invention provides an adeno-associated virus (AAV) vector gene therapy comprising a vascular endothelial growth factor (VEGF) C transgene; and a minimal nephropathy protein promoter NPHS1 or a podocyte promoter NPHS2. The gene therapy vector can be used for targeting podocytes in the glomerulus to treat or prevent kidney diseases, such as diabetic nephropathy. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SALEEM-UDDIN MUHAMMAD A |4 aut | |
| 700 | 0 | |a WELSH GREGORY I |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 08. Nov. |
| 773 | 1 | 8 | |g year:2022 |g day:08 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/70278767/publication/CN115315517A1?q=CN115315517 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 08 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 08 |c 11 | ||